# Investigating the Combination of Bexmarilimab and Nivolumab in Solid Tumours, Melanoma and NSCLC

> **NCT07718243** · PHASE1,PHASE2 · RECRUITING · sponsor: **Institute of Cancer Research, United Kingdom** · enrollment: 62 (estimated)

## Conditions studied

- Melanoma (Skin Cancer)
- Non Small Cell Lung Cancer
- Solid Tumor in Advanced Stage

## Interventions

- **DRUG:** Bexmarilimab 1mg/kg and nivolumab 1mg/kg
- **DRUG:** Bexmarilimab 3mg/kg and nivolumab 1mg/kg
- **DRUG:** Recommended Phase II Dose

## Key facts

- **NCT ID:** NCT07718243
- **Lead sponsor:** Institute of Cancer Research, United Kingdom
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-08-28
- **Primary completion:** 2030-01-31
- **Final completion:** 2030-01-31
- **Target enrollment:** 62 (ESTIMATED)
- **Last updated:** 2026-09-08

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07718243

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07718243, "Investigating the Combination of Bexmarilimab and Nivolumab in Solid Tumours, Melanoma and NSCLC". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07718243. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*